Incyte | INCY - Nettoeinkommen

Aktienkurs
96.45
Täglich Wechseln
1.18 1.24%
Monatlich
0.54%
Jährlich
54.25%
Q2 Prognose
92.62




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agenus USD -10.63M 74.49M 2025-12
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Exelixis USD 193.58M 8.73M 2025-09
Gilead Sciences USD 2.18B 869M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
MacroGenics USD -14.16M 30.98M 2025-12
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 3.16B 747M 2026-03
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12